Skip to main content

Table 1 Study participant characteristics

From: Jo-1 autoantigen-specific B cells are skewed towards distinct functional B cell subsets in anti-synthetase syndrome patients

  Healthy controls (n = 8) Non-Jo-1 IIM* (n = 4) Stable Jo-1+ disease** (n = 5) Active Jo-1 disease*** (n = 5)
Age (years) 48.2 (42.1–52.0) 58.2 (50.9–63.2) 57.1 (43.4–57.4) 53.8 (46.2–56.1)
Sex (female) 5 (63) 3 (75) 5 (100) 3 (60)
Race
 Caucasian 6 (75) 4 (100) 5 (100) 3 (60)
 African American 1 (13) 0 0 2 (40)
 Other ethnicity 1 (13) 0 0 0
Disease duration (years) 2 (0.5–2.7) 13.8 (4.6–14.5) 1.0 (0.8–4.0)
Daily steroid dose ≥ 20 mg 3 (75) 0 4 (80)
Other immunosuppressant use 2 (50) 5 (100) 1 (20)§
  1. Data are presented as medians (interquartile ranges) and counts (percentages) for continuous and categorical data, respectively
  2. *Anti-PL-7, anti-EJ with anti-Ro52, anti-Mi-2, and anti-TIF1-γ
  3. **Stable Jo-1+ anti-synthetase syndrome defined as having no medication changes discussed, and current medications either continued or de-escalated at the time of blood draw
  4. ***Active Jo-1+ anti-synthetase syndrome defined as either immunosuppression increased during outpatient visit, or patient hospitalized with life-threatening disease at the time of blood draw
  5. IVIG (1), methotrexate (1)
  6. Azathioprine (3), hydroxychloroquine (1), leflunomide (1)
  7. §IVIG (1)